Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 11/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 2/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | CD38 | P28907 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16159122 | 0.90 | PDK2 (0.43) | PDK2DYRK1AKDRDYRK2DYRK1B | |
| SCHEMBL16159620 | 0.90 | KDR (0.42) | PDK2DYRK1AKDRDYRK2DYRK1B | |
| SCHEMBL16159763 | 0.88 | KDR (0.39) | PDK2DYRK1AKDRDYRK2DYRK1B | |
| SCHEMBL16159442 | 0.83 | PIM1 (0.41) | PDK2DYRK1AKDRDYRK2DYRK1B | |
| SCHEMBL16159788 | 0.82 | DYRK1A (0.39) | PDK2DYRK1AKDRDYRK2DYRK1B | |
| SCHEMBL16159234 | 0.80 | PDK2 (0.38) | PDK2DYRK1AKDRPIM1IDO1 | |
| SCHEMBL16159125 | 0.80 | PDK2 (0.36) | PDK2DYRK1AKDRPIM1CD38 | |
| SCHEMBL16159641 | 0.79 | KDR (0.35) | PDK2DYRK1AKDRPIM1CHEK1 | |
| SCHEMBL16159121 | 0.78 | KDR (0.42) | PDK2DYRK1AKDRDYRK2DYRK1B | |
| SCHEMBL16159752 | 0.78 | CYP2A6 (0.44) | PDK2KDRCHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160118598-A1 | ELECTRON TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | JNC CORPORATION (JP) | 2016-04-28 | — | — | US | disclosed |
| US-20160118598-A1 | ELECTRON TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | JNC CORPORATION (JP) | 2016-04-28 | — | — | US | disclosed |
| WO-2014163173-A1 | ELECTRON TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | JNC株式会社 (JP) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160118598-A1 | ELECTRON TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING SAME | HVCN1, VDAC1, SLC26A3 | PDK2 2391/4885DYRK1A 3602/4885KDR 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.